Meetings & Presentations2026-11-15

Aleniglipron (GSBR-1290) - (ACCESS and ACCESS II )

Structure Therapeutics Inc.GPCR
Indication
Type 2 Diabetes, obesity
Stage
phase3
Event
Conference Presentation
Details

October 19, 2026: Structure Therapeutics Inc. (NASDAQ: GPCR) announced upcoming ObesityWeek 2026 poster presentations on aleniglipron (GSBR-1290), an investigational once-daily oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes.

At The Obesity Society’s Annual Meeting (ObesityWeek), November 14–17, 2026 in National Harbor, Maryland, the company will present:

  • “Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension” on November 15, 2026, 2:30–3:30 p.m. ET, Exhibit Hall BCD.
  • “Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials” on November 15, 2026, 2:30–3:30 p.m. ET, Exhibit Hall BCD.

The announcement is a conference presentation catalyst for aleniglipron in overweight/obesity. No efficacy or safety results were disclosed in the provided content.